Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt No Debt
OHRP's Cash-to-Debt is ranked higher than
87% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. OHRP: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OHRP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 173.67 Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -2.23
WACC vs ROIC
12.06%
-219.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -86.20
OHRP's ROE % is ranked lower than
76% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. OHRP: -86.20 )
Ranked among companies with meaningful ROE % only.
OHRP' s ROE % Range Over the Past 10 Years
Min: -267.49  Med: -66.72 Max: 427.71
Current: -86.2
-267.49
427.71
ROA % -75.25
OHRP's ROA % is ranked lower than
79% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. OHRP: -75.25 )
Ranked among companies with meaningful ROA % only.
OHRP' s ROA % Range Over the Past 10 Years
Min: -1157.76  Med: -63.5 Max: 37.38
Current: -75.25
-1157.76
37.38
ROC (Joel Greenblatt) % -13026.07
OHRP's ROC (Joel Greenblatt) % is ranked lower than
90% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. OHRP: -13026.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OHRP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -23716.28  Med: -10980.36 Max: 4300
Current: -13026.07
-23716.28
4300
3-Year EBITDA Growth Rate 36.00
OHRP's 3-Year EBITDA Growth Rate is ranked higher than
84% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. OHRP: 36.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OHRP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.4 Max: 82.7
Current: 36
0
82.7
3-Year EPS without NRI Growth Rate 39.80
OHRP's 3-Year EPS without NRI Growth Rate is ranked higher than
86% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. OHRP: 39.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OHRP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -1  Med: 22.2 Max: 75.4
Current: 39.8
-1
75.4
GuruFocus has detected 2 Warning Signs with Ohr Pharmaceutical Inc $OHRP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OHRP's 10-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

OHRP Guru Trades in Q3 2015

George Soros Sold Out
» More
Q2 2016

OHRP Guru Trades in Q2 2016

Jim Simons 21,809 sh (New)
» More
Q3 2016

OHRP Guru Trades in Q3 2016

Jim Simons 50,609 sh (+132.06%)
» More
Q4 2016

OHRP Guru Trades in Q4 2016

Jim Simons 67,109 sh (+32.60%)
» More
» Details

Insider Trades

Latest Guru Trades with OHRP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:EARS, NAS:THLD, OTCPK:ANTB, OTCPK:GBLX, NAS:AEZS, NAS:PTIE, NAS:DFFN, NAS:CHMA, NAS:XBIO, OTCPK:FENCF, OTCPK:NWBO, NAS:HSGX, AMEX:IBIO, NAS:MRNS, OTCPK:USRM, NAS:TPIV, NAS:CYTX, OTCPK:PRTX, OTCPK:IMROY, NAS:APVO » details
Traded in other countries:O7P1.Germany,
Headquarter Location:USA
Ohr Pharmaceutical Inc is a pharmaceutical company engaged in development of novel therapeutics and delivery technologies for the treatment of ocular disease.

Ohr Pharmaceutical Inc is a Delaware corporation organized on August 4, 2009, as successor to, BBM Holdings, Inc., pursuant to a reincorporation merger. The Company is a pharmaceutical company engaged in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The Company has submitted a Special Protocol Assessment (SPA) request to the FDA, as part of its ongoing interactions with the FDA on the detailed design of the Phase III clinical development program of OHR-102. The drug acts against the development of aberrant neovascularization by inhibiting multiple protein growth factors of angiogenesis, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and basic fibroblast growth factor growth factor (bFGF). The Company is subject to regulation by federal, state and local government authorities, including the FDA.

Top Ranked Articles about Ohr Pharmaceutical Inc

Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants
Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
Ohr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive Officer, will provide a corporate overview at the Cowen & Company 37th Annual Health Care Conference, taking place March 6-8 at the Boston Marriott Copley Place in Boston Massachusetts.
Ohr Pharmaceutical Presentation Details    
Date:Monday, March 6Time: 4:40pm Eastern TimeLocation:                Regis Ballroom, 3rd Floor  About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as Squalamine or OHR-102), is currently being studied as an eye drop formulation in a clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact:
Ohr Pharmaceutical Inc.
Investor Relations
888-388-2327
[email protected]

LifeSci Advisors, LLC
Michael Wood
646-597-6983
[email protected]


Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.90
OHRP's PB Ratio is ranked higher than
91% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. OHRP: 0.90 )
Ranked among companies with meaningful PB Ratio only.
OHRP' s PB Ratio Range Over the Past 10 Years
Min: 0.89  Med: 13.89 Max: 17.86
Current: 0.9
0.89
17.86
EV-to-EBIT -0.60
OHRP's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. OHRP: -0.60 )
Ranked among companies with meaningful EV-to-EBIT only.
OHRP' s EV-to-EBIT Range Over the Past 10 Years
Min: -101.5  Med: -14.6 Max: -0.59
Current: -0.6
-101.5
-0.59
EV-to-EBITDA -0.62
OHRP's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. OHRP: -0.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
OHRP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -101.5  Med: -14.6 Max: -0.61
Current: -0.62
-101.5
-0.61
Current Ratio 3.57
OHRP's Current Ratio is ranked lower than
55% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. OHRP: 3.57 )
Ranked among companies with meaningful Current Ratio only.
OHRP' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.53 Max: 24.65
Current: 3.57
0.04
24.65
Quick Ratio 3.57
OHRP's Quick Ratio is ranked lower than
52% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. OHRP: 3.57 )
Ranked among companies with meaningful Quick Ratio only.
OHRP' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.53 Max: 24.65
Current: 3.57
0.04
24.65

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.60
OHRP's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. OHRP: -17.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OHRP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -129.9  Med: -23.2 Max: 10.2
Current: -17.6
-129.9
10.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.43
OHRP's Price-to-Net-Cash is ranked higher than
79% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. OHRP: 2.43 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OHRP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.4  Med: 25.49 Max: 155
Current: 2.43
2.4
155
Price-to-Net-Current-Asset-Value 2.35
OHRP's Price-to-Net-Current-Asset-Value is ranked higher than
80% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. OHRP: 2.35 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OHRP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.32  Med: 24.24 Max: 155
Current: 2.35
2.32
155
Price-to-Tangible-Book 2.28
OHRP's Price-to-Tangible-Book is ranked higher than
71% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. OHRP: 2.28 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OHRP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.27  Med: 17.07 Max: 450
Current: 2.28
2.27
450
Earnings Yield (Greenblatt) % -165.14
OHRP's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. OHRP: -165.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OHRP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10230.94  Med: 0 Max: 0
Current: -165.14
-10230.94
0

More Statistics

EPS (TTM) $ -0.83
Beta1.64
Short Percentage of Float1.60%
52-Week Range $0.60 - 4.05
Shares Outstanding (Mil)56.21

Analyst Estimate

Sep18
Revenue (Mil $)
EPS ($) -1.28
EPS without NRI ($) -1.28
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OHRP

Headlines

Articles On GuruFocus.com
Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD Apr 10 2017 
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants Apr 10 2017 
Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants Apr 05 2017 
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants Apr 04 2017 
Ohr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference Mar 02 2017 
CEO Invests in Ohr Pharmaceutical Jan 21 2016 
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 

More From Other Websites
Ohr Pharmaceutical (OHRP) Jumps: Stock Adds 15% in Session Apr 18 2017
Ohr Pharmaceutical Provides Update on Squalamine Study Apr 11 2017
Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD Apr 10 2017
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants Apr 10 2017
Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants Apr 05 2017
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants Apr 04 2017
Ohr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference Mar 02 2017
The Market Has Got Its Interpretation Of The OHR Pharmaceutical Inc (OHRP) Announcement Wrong Feb 15 2017
Ohr Pharmaceutical Reports 4Q Loss, Suspends Trial Feb 15 2017
Ohr Pharmaceutical Announces Strategic Update and Fiscal First Quarter 2017 Earnings Feb 14 2017
Ohr Pharmaceutical to Announce First Quarter 2017 Financial Results on February 14 Feb 13 2017
Post Earnings Coverage as Ohr Pharma Reported Annual Results; Announced Closure of Public Offering Jan 05 2017
Ohr Pharmaceutical, Inc. :OHRP-US: Earnings Analysis: Q4, 2016 By the Numbers : December 27, 2016 Dec 27 2016
Which Wet AMD Stock Would You Buy Right Now? Dec 14 2016
What Fovista's Fail Means For OHR Pharma Dec 13 2016
Ohr Pharmaceuticals Expects $8M from Public Offering Dec 09 2016
Ohr Pharma Drops on Secondary Offering Dec 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)